OAM
GNOM icon

Oppenheimer Asset Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Oppenheimer Asset Management’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$992K Sell
17,449
-90
-0.5% -$4.29K 0.01% 745
2026
Q1 		$767K Sell
17,539
-3,493
-17% -$162K 0.01% 788
2025
Q4 		$956K Sell
21,032
-1,009
-5% -$44.7K 0.01% 682
2025
Q3 		$856K Sell
22,041
-367
-2% -$13.3K 0.01% 792
2025
Q2 		$756K Buy
22,408
+1,677
+8% +$53.1K 0.01% 796
2025
Q1 		$659K Buy
20,731
+5,462
+36% +$207K 0.01% 800
2024
Q4 		$593K Sell
15,269
-159
-1% -$6.68K 0.01% 829
2024
Q3 		$694K Sell
15,428
-1,500
-9% -$67.1K 0.01% 803
2024
Q2 		$707K Buy
16,928
+1,565
+10% +$65.4K 0.01% 781
2024
Q1 		$699K Sell
15,363
-263
-2% -$12K 0.01% 767
2023
Q4 		$722K Buy
15,626
+2,097
+16% +$85.5K 0.01% 782
2023
Q3 		$550K Buy
13,529
+1,400
+12% +$63.7K 0.01% 827
2023
Q2 		$588K Buy
12,129
+367
+3% +$18.4K 0.01% 822
2023
Q1 		$580K Buy
11,762
+608
+5% +$31.3K 0.01% 815
2022
Q4 		$564K Sell
11,154
-491
-4% -$25.3K 0.01% 820
2022
Q3 		$585K Buy
11,645
+48
+0.4% +$2.71K 0.01% 794
2022
Q2 		$567K Buy
11,597
+378
+3% +$19.2K 0.01% 825
2022
Q1 		$674K Buy
11,219
+2,402
+27% +$151K 0.01% 849
2021
Q4 		$700K Buy
8,817
+1,628
+23% +$137K 0.01% 879
2021
Q3 		$637K Buy
7,189
+1,486
+26% +$139K 0.01% 870
2021
Q2 		$568K Buy
5,703
+1,198
+27% +$106K 0.01% 914
2021
Q1 		$405K Buy
+4,505
New +$445K 0.01% 969

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return
SH
SLT Holdings Scottsdale, Arizona $160M AUM 52.3% 1-Year Est. Return

Oppenheimer Asset Management's GNOM Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 0.51% in Q2 2026, selling an estimated $4.29K and leaving 17,449 shares worth $992K. The position accounts for 0.01% of the portfolio, ranked #745.

Oppenheimer Asset Management first reported a position in GNOM in Q1 2021 and has held it in 22 quarters since. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

  • Oppenheimer Asset Management held 17,449 shares of Global X Genomics & Biotechnology ETF worth $992K as of Q2 2026.
  • Oppenheimer Asset Management sold 90 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $4.29K.
  • Global X Genomics & Biotechnology ETF made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #745 holding.
  • Oppenheimer Asset Management first reported a position in Global X Genomics & Biotechnology ETF in Q1 2021 and has held it in 22 quarters since.
  • 48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.